SEC Filings
Arbutus Argues Hepatitis B Cure Tally Could Rise To 11 From 10
Long-term follow-up showed five of eight patients maintained functional cure, while three lost that status but stayed partial cures.
Arbutus Biopharma (ABUS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Long-term follow-up showed five of eight patients maintained functional cure, while three lost that status but stayed partial cures.
SEC Filings
A Genevant dividend helped produce a quarterly profit, while Arbutus paid $230 million to repurchase shares in early October.
SEC Filings
The company says it may now pursue more U.S. clinical development of AB-101 and is evaluating next steps for the oral PD-L1 inhibitor.
SEC Filings
A Schedule 13D/A says Roivant sold into Arbutus's buyback only to hold its ownership percentage, with no new demands.